They regulate appetite, slow gastric emptying, and improve metabolic function
Last reviewed: May 23, 2026 Last updated: May 23, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
This includes the structurally similar liraglutide (once daily, t 1/2 = 13 h), semaglutide (once weekly, t 1/2 = 165185 h), dulaglutide (once weekly, t 1/2 = 90 h), the more dissimilar Exendin-4 (Exenatide
Competitive Landscape for Market Players The GLP-1 receptor agonist market is characterized by a concentrated competitive landscape dominated by Novo Nordisk and Eli Lilly, with emerging challengers advancing next-generation molecules
Increasingly, the answer may involve treating obesity, diabetes, cardiovascular disease, and kidney disease as interconnected conditions rather than separate problems